Omeros (NASDAQ:OMER) Stock Rating Upgraded by StockNews.com

Omeros (NASDAQ:OMER) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

A number of other brokerages also recently commented on OMER. D. Boral Capital restated a “buy” rating and set a $36.00 price objective on shares of Omeros in a research report on Thursday, February 20th. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research report on Friday, January 17th. RODMAN&RENSHAW upgraded shares of Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. Finally, Rodman & Renshaw assumed coverage on shares of Omeros in a research note on Thursday, November 14th. They set a “buy” rating and a $9.00 price target on the stock. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Stock Performance

Shares of Omeros stock opened at $8.01 on Thursday. The company has a market cap of $464.18 million, a P/E ratio of -3.47 and a beta of 2.03. Omeros has a one year low of $2.61 and a one year high of $13.60. The firm has a fifty day moving average of $8.90 and a two-hundred day moving average of $7.12.

Hedge Funds Weigh In On Omeros

Institutional investors and hedge funds have recently made changes to their positions in the stock. Truvestments Capital LLC grew its stake in shares of Omeros by 116.5% during the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 1,669 shares during the period. Tower Research Capital LLC TRC grew its stake in Omeros by 79.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 1,972 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Omeros in the 4th quarter valued at about $46,000. Picton Mahoney Asset Management grew its stake in Omeros by 692.5% in the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 4,404 shares during the last quarter. Finally, US Bancorp DE acquired a new stake in Omeros in the 4th quarter valued at about $81,000. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.